I'm not harping so much as I am just stirring the pot. I am entertained with the bi-polar behavior of certain investors. But I can see how it might be interpreted otherwise. I should probably just put certain posters back on ignore and let them wallow in their random concerns.

Regarding the LymPro launch, Gerald has stated we were waiting until we have the data to back up our claims in any marketing campaign we might do. Word will certainly spread among researchers and in the medical community, but one would think all it would take is a call to 60 Minutes to get feature story coverage and make a huge impact on public perception of our company, especially since we have the data to back up our claims, and we can show the test is already being used in AD clinical drug trials. It will be interesting to see how this unfolds.